Early Phase Clinical Trial Units

The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, carried out in an expeditious and efficient manner, aided by bioanalysis when necessary, against viral, bacterial, parasitic, and fungal pathogens and emerging and re-emerging infectious diseases. The candidate products assessed through the EPCTUs may include licensed or investigational products such as small molecules, monoclonal antibodies, i

Therapeutic Development Services - Interventional Agents

Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

Note: Devices are excluded.

In Vitro Assessment for Antimicrobial Activity Program

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.

This is one of several programs provided by NIAID's Division of Microbiology and Infectious Diseases to support infectious disease product developers.

Therapeutic Development Services - Biopharmaceutical Products

Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

Genomic Centers for Infectious Diseases (GCID) Resources

The GCID use, develop and improve innovative applications of genomic technologies, such as DNA and RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes.

Preclinical Models of Infectious Disease

This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo and complex human cell-based in vitro model preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

BEI Resources Repository

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog. There is no charge for research materials, but domestic investigators will be required to pay for shipping costs.

Cholera Treatment and Prevention

Cholera Biology and Genetics

Cholera is an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae. An estimated 3-5 million cases and over 100,000 deaths occur each year around the world. The infection is often mild or without symptoms, but can sometimes be severe. Approximately one in 10 (5 to 10 percent) infected persons will have severe disease characterized by profuse watery diarrhea, vomiting, and leg cramps. In these people, rapid loss of body fluids leads to dehydration and shock. Without treatment, death can occur within hours.

Why Is the Study of Cholera a Priority for NIAID?

Because the bacteria that cause cholera, Vibrio cholerae, are spread through contaminated water, cholera is not a public health issue in countries where drinking water and sewage are separated and treated. It is unlikely that a large outbreak of cholera would occur in the United States or other developed countries, but cholera epidemics are a very big public health concern in Haiti, India, and other developing areas of the world.

How Is NIAID Addressing This Critical Topic?

NIAID-supported scientists conducting basic cholera research are studying the evolution and genetics of V. cholerae, and how the micro-organism interacts with environmental factors. Scientists are exploring several approaches to develop improved vaccines for cholera, and are devising new drugs based on small molecules and natural products to treat cholera and other related diarrheal diseases.

Related Public Health and Government Information

To learn about risk factors for Cholera and current prevention and treatment strategies visit the MedlinePlus cholera site.

Image of cholera
Image of Vibrio cholerae

Vibrio cholerae

Credit: CDC
Cholera
Page Summary
Cholera is an acute, diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae. An estimated 3-5 million cases and over 100,000 deaths occur each year around the world. The infection is often mild or without symptoms, but can sometimes be severe. Without treatment, death can occur within hours.
Research Area Type
Diseases & Conditions